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Abstract
Human UDP-glucuronosyltransferases (UGTs) are important enzymes in metabolic elimination of endo- and xenobiotics. It
was recently shown that addition of fatty acid free bovine serum albumin (BSA) significantly enhances in vitro activities of
UGTs, a limiting factor in in vitro–in vivo extrapolation. Nevertheless, since only few human UGT enzymes were tested for
this phenomenon, we have now performed detailed enzyme kinetic analysis on the BSA effects in six previously untested
UGTs, using 2–4 suitable substrates for each enzyme. We also examined some of the previously tested UGTs, but using
additional substrates and a lower BSA concentration, only 0.1%. The latter concentration allows the use of important but
more lipophilic substrates, such as estradiol and 17-epiestradiol. In five newly tested UGTs, 1A7, 1A8, 1A10, 2A1, and 2B15,
the addition of BSA enhanced, to a different degree, the in vitro activity by either decreasing reaction’s Km, increasing its
Vmax, or both. In contrast, the activities of UGT2B17, another previously untested enzyme, were almost unaffected. The
results of the assays with the previously tested UGTs, 1A1, 1A6, 2B4, and 2B7, were similar to the published BSA only as far
as the BSA effects on the reactions’ Km are concerned. In the cases of Vmax values, however, our results differ significantly
from the previously published ones, at least with some of the substrates. Hence, the magnitude of the BSA effects appears
to be substrate dependent, especially with respect to Vmax increases. Additionally, the BSA effects may be UGT subfamily
dependent since Km decreases were observed in members of subfamilies 1A, 2A and 2B, whereas large Vmax increases were
only found in several UGT1A members. The results shed new light on the complexity of the BSA effects on the activity and
enzyme kinetics of the human UGTs.
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Introduction
The human UDP-glucuronosyltransferase enzymes (UGTs) are
located in the membrane of endoplasmic reticulum and play
important roles in the metabolic elimination of lipophilic organic
molecules of either external (xenobiotic) or internal origin [1,2].
These enzymes transfer the glucuronic acid moiety from the
cosubstrate, UDP-a-D-glucuronic acid (UDPGA), to nucleophilic
groups on aglycone substrates that can vary considerably in
chemical structure and physicochemical properties. Conjugation
with glucuronic acid usually diminishes the pharmacodynamic
activity of drugs and active drug metabolites, and also makes them
more susceptible to excretion [3]. Since many drugs are subjected
to glucuronidation, either directly or after phase I drug
metabolizing reactions, the activity of UGTs may significantly
affect their pharmacodynamic and pharmacokinetic profiles. As a
result, improving methods for the prediction of UGT activity is an
important research goal in drug development.
The main goal of in vitro glucuronidation assays is to accurately
predict in vivo drug glucuronidation, both qualitatively and
quantitatively [2]. Therefore, careful optimization of assay
conditions is crucial for successful extrapolation of the in vitro
results into valid conclusions about the in vivo UGTs activity. The
inclusion of fatty acid free bovine serum albumin (abbreviated here
as BSA even if not all BSA types are fatty acid free) was previously
reported to significantly increase the in vitro activities of UGT1A9
and 2B7, regardless of whether recombinant enzymes or human
liver microsomes (HLM) were used as an enzyme source [4–9].
Added BSA presumably binds lipophilic UGT inhibitors, such
as fatty acids released from cells that are damaged during the
preparation of HLM or recombinant UGT-enriched membranes
[5]. The first studies on the BSA effects centered on UGT2B7,
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catalyzing zidovudine glucuronidation, and revealed that BSA
inclusion largely lowers the reaction’s Km (provided substrate
binding to BSA is taken into account), but with only a marginal
effect on the reaction’s Vmax, indicating that it increases the
apparent substrate affinity [4,5]. Similar effects of BSA inclusion
were reported for 4-methylumbelliferone (4-MU) and propofol
glucuronidation by UGT1A9 [6]. Subsequent studies from our
laboratory demonstrated that while the BSA effects on UGT2B7
are reproducible, its effects on the activity of UGT1A9 are
somewhat different since, in this case, it both lowers the Km and
increases the Vmax values [8,9]. The BSA effects on the activity of
some other human UGTs were also tested, although not as
thoroughly as with UGT2B7 and UGT1A9. It was reported that
the BSA effects on UGT1A1 and UGT1A6 [6,10], UGT1A4
[10,11], and UGT2B4 [12] are generally minor.
The BSA effects are probably caused by the removal of
lipophilic UGT inhibitors that were released during cells
disruption. The differences in lipid composition between HLM,
HEK293, or Sf9 insect cells may affect the manifestation of the
BSA effects and might lead to differences in this respect between
recombinant UGTs that were expressed in different systems, as
well as between recombinant UGTs and the native ones in HLM.
Based on the available experimental evidence, however, the
differences in the BSA effects between HLM and recombinant
UGTs that were expressed either in HEK293 cells [4–6], or Sf9
insect cells [8,10,12] are minor and most of the findings
[4,6,8,10,12] suggest that, for a given UGT enzyme, the
differences in lipid composition between HEK293 and Sf9 insect
cells are not large enough to play a crucial role in the
manifestation of BSA effects between different enzyme sources.
Nevertheless, this does not exclude significant differences between
different human UGT enzymes.
The possible major BSA impact on the in vitro activities of
some UGTs and the variability in these effects among them
prompted us to examine it in UGTs that have not been tested
before. In addition, we tried to clarify, both in previously tested
and the newly tested enzymes, whether or not the BSA effects are
specific substrate and/or individual UGT dependent. Better and
deeper understanding of the BSA effects on individual human
UGTs will help us to improve the in vitro drug glucuronidation
assays and, perhaps, to identify the site, or sites of inhibition. This,
in turn, will teach us about the functions and mechanism of these
complex enzymes.
We have now studied the BSA effects on ten different
recombinant UGTs, six previously untested, namely 1A7, 1A8,
1A10, 2A1, 2B15, and 2B17, and four that were previously
examined, UGTs 1A1, 1A6, 2B4 and 2B7, but mainly with
different substrates and at a different BSA concentration. After
careful optimization of assay conditions and measurement of
substrates’ binding to BSA, we studied the enzyme kinetics of each
of these recombinant UGTs in the absence and presence of BSA.
The results of this extensive analysis are presented and discussed
below.
Materials and Methods
Compounds and Reagents
4-Methylumbelliferone (4-MU; .99%, CAS 90-33-5), 1-naph-
thol ($99%, CAS 90-15-3), 17a-estradiol ($98%, CAS 57-91-0),
17b-estradiol ($98%, CAS 50-28-2), UDP-a-D-glucuronic acid
(UDPGA; ammonium salt, 98–100%, CAS 43195-60-4), 4-
methylumbelliferone-b-D-glucuronide ($98%, CAS 6160-80-1),
1-naphthol-b-D-glucuronide (.99%, CAS 83833-12-9), 17b-
estradiol-17-b-D-glucuronide ($98%, CAS 15087-02-2), 17b-
estradiol-3-b-D-glucuronide ($98%, CAS 14982-12-8), sodium
phosphate monobasic dihydrate ($99%, CAS 13472-35-0), and
bovine serum albumin (BSA, $96%, CAS 9048-46-8, essentially
fatty acid free, #0.01%) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Entacapone (batch: 1044842) was a generous
gift from Orion Pharma (Espoo, Finland). Entacapone-b-D-
glucuronide was synthesized in our laboratory as described
previously [13]. Magnesium chloride hexahydrate and perchloric
acid were obtained from Merck (Darmstadt, Germany). Formic
acid (98–100%) was from Riedel-deHae¨n (Seelze, Germany).
Disodium hydrogen phosphate dihydrate was purchased from
Fluka (Buchs, Switzerland). Dimethyl sulfoxide and solvents used
for HPLC analyses were of liquid chromatography–mass spec-
trometry grade.
We have chemically synthesized 6-hydroxyindole by catalytic
hydrogenation of 6-benzyloxyindole (.98.0%, CAS 15903-94-3,
TCI Europe, Zwijndrecht, Belgium). The catalyst (Pd, 10% on
activated carbon, 0.20 g, Sigma-Aldrich, St. Louis, MO, USA)
was placed into two-necked 100 mL round-bottomed flask under
inert atmosphere of argon. Methanol (20 mL) was then added,
followed by a solution of 6-benzyloxyindole (0.30 g, 1.35 mmol) in
methanol (20 mL). At this stage the argon atmosphere was
replaced by dihydrogen and the reaction mixture was stirred at
room temperature. The progress of the reaction was monitored by
thin-layer chromatography on silica gel 60 F254 plates (Merck,
Darmstadt, Germany) with n-hexane/ethyl acetate = 2:1 eluent
and UV detection at 254 nm (Rf = 0.3). After 2 h the reaction
mixture was filtrated using the sinter funnel and CeliteH 545
filtrating agent (CAS 68855-54-9, Sigma-Aldrich, St. Louis, MO,
USA). The crude product was purified by Biotage high-
performance flash chromatography Sp1 system (Uppsala, Sweden)
using a 0.1 mm pathlength flow cell UV detector (fixed
wavelength at 254 nm), Biotage SNAP 10 g flash cartridge, and
n-hexane/ethyl acetate = 2:1 mobile phase. The appropriate
fractions were combined, and solvents were evaporated to dryness
in vacuo to give 6-hydroxyindole (0.11 g, 0.83 mmol) as pale orange
solids in 61% yield. The 1H NMR and 13C NMR spectra were
recorded on a Varian Mercury 300 MHz (Varian, Palo Alto, CA,
USA) as solutions in [D6]DMSO (Sigma-Aldrich, St. Louis, MO,
USA). Multiplicities are indicated by s (singlet), d (doublet), dd
(doublet of doublets), and m (multiplet). Chemical shifts (d) are
given in ppm relative to the residual DMSO signal: 2.50 and
39.52 ppm for 1H and 13C NMR, respectively. 1H NMR
(300 MHz), d (ppm): 10.63 (s, 1H), 8.82 (s, 1H), 7.28 (d, 1H,
J=8.4 Hz), 7.08 (dd, 1H, J=3.3, 2.7 Hz), 6.74 (d, 1H,
J=2.4 Hz), 6.51 (dd, 1H, J=8.4, 2.1 Hz), 6.26–6.24 (m, 1H).
13C NMR (75 MHz), d (ppm): 152.8, 136.9, 123.1, 120.9, 120.2,
109.4, 100.8, and 96.4. The gas chromatograph–mass spectrom-
etry (GC–MS) system consisted of the 5890A gas chromatograph
and a 5970 mass selective detector (Hewlett Packard, Palo Alto,
CA, USA) equipped with HP5–MS 12 m60.25 mm column
(Agilent Technologies, Palo Alto, CA, USA); GC–MS: m/z 133
[M]+, 104, 77, 51; Rt = 10.0 min. The HPLC-UV analysis was
performed with Agilent 1100 HPLC instrument, Poroshell 120
EC-C18 column (4.66100 mm, 2.7 mm; Agilent Technologies,
Palo Alto, CA, USA), and UV detection at 254 nm (see Analytical
methods below). Melting point was recorded on IA9100 digital
melting point apparatus (Electrothermal Engineering Ltd., Essex,
UK); mp= 124–129uC. The 6-hydroxyindole purity was assessed
as 99% by 1H NMR, GC–MS, and HPLC-UV analyses.
Enzyme Sources
Recombinant human UGTs 1A1, 1A6, 1A7, 1A8, 1A10, 2A1,
2B4, 2B7 and 2B17 were expressed as His-tagged proteins in
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baculovirus-infected insect cells as described previously [14].
Control samples, insect cell membranes without any human
UGT, were prepared in the similar way by infecting the insect cells
with baculovirus that does not encode any human UGT.
Recombinant human UGT2B15 was purchased from BD
Biosciences (Woburn, MA, USA; lot. 69457). Protein concentra-
tions were determined by the BCA method (Pierce Biotechnology,
Rockford, IL, USA).
Drug Binding Assays
We measured the binding of 17a-estradiol, 17b-estradiol, and 6-
hydroxyindole to 0.1% BSA and control insect cell membranes by
rapid equilibrium dialysis (RED; Thermo Scientific, Rockford, IL,
USA) as previously described [8]. The binding assays with 17a-
and 17b-estradiol contained 1% DMSO in both sample and buffer
chambers. The equilibration time was 8 h for the estradiols and
6 h for the 6-hydroxyindole binding assay. Nonspecific binding of
the two estradiol isomers to the RED devices was rather high,
nearly 40%. Nevertheless, due to the concentration independent
nature of the estradiols binding to 0.1% BSA (see below), the non-
specific binding to the RED device did not significantly affect the
final result. The nonspecific binding of 6-hydroxyindole to the
RED device was negligible (#10%). The concentration range for
the 17a-estradiol and 17b-estradiol was 2–100 mM, whereas for 6-
hydroxyindole it was 5–750 mM. The unbound fraction of the test
compound, fu, was calculated as follows:
fu~
S½ buffer
S½ sample
where [S]buffer and [S]sample are concentrations of the test
compounds in the corresponding chambers.
Drug Glucuronidation Assays
Stock solutions of all substrates were prepared in methanol
and diluted with methanol to the desired concentrations before
use. Appropriate amounts of these dilutions were transferred
into 1.5 mL centrifuge tubes and the solvent was evaporated in
vacuo at ambient temperature. The solvent was evaporated to
avoid the presence of organic solvents in the incubation mixture.
The solid residues were dissolved in the reaction mixture
containing phosphate buffer (50 mM, pH 7.4), MgCl2 (10 mM),
different BSA concentration (0.0, 0.1, or 1%), and enzyme
source (0.02–0.2 mg/mL of total sample protein, depending on
the enzyme source), to a final volume of 100 mL. The reactions
with the two estradiol isomers, as well as reactions with 4-MU
and 1-naphthol where the substrate concentrations exceeded
1000 mM, were performed in the presence of 1% DMSO.
Alamethicin was not added to the incubations since it has no
significant effect on the glucuronidation activity of recombinant
UGTs [15,16].
The mixtures were first incubated for 20 min at 0uC, followed
by 5 min at 37uC, and the reaction was then initiated by the
addition of UDPGA to a final concentration of 5000 mM. The
20 min preincubation at 0uC was performed to facilitate the
dissolution of substrates in the reaction mixture, as well as to keep
general consistency with HLM and HIM assays that are treated in
this way due to the use of alamethicin (even if HLM and HIM
assays were not included in this work) [17,18]. The 5 min
preincubation at 37uC was performed to prewarm the reaction
mixture to the assay temperature. The reactions were carried out
at 37uC for 10–60 min, protected from light. Negative controls,
including reactions without UDPGA or without the aglycone
substrate, were carried out for each set of assays. The
glucuronidation reactions were terminated either by the addition
of 60 mL ice-cold 4 M perchloric acid/methanol (1:5 mix) or, in
the case of the estradiols glucuronidation assays, by the addition of
100 mL 5% acetic acid in methanol. Following reaction termina-
tion, the tubes were kept at –20uC for 30–60 min and then
centrifuged at 16000 g for 5 min. Aliquots of the resulting
supernatants were transferred to dark glass vials and subjected to
HPLC or UPLC analyses.
The protein concentrations and incubation times for the
enzyme kinetic assays were selected based on preliminary assays
in order to ensure that the product formation was within the linear
range with respect to both protein concentration and time, and
that the substrate consumption during the reaction was less than
10%. The initial velocity measurements were performed in either
duplicates or triplicates and they are presented as the average
values and S.E.
The glucuronidation rates by recombinant enzymes are
reported as ‘‘expression normalized’’ values. The relative expres-
sion level of each recombinant UGT that was produced in our
laboratory was determined using immunoblotting, as previously
described [14,19]. The dot blot assays were performed in triplicate
and the average value was used for normalization. The relative
expression level of UGT1A10 was set to 1.00 and, in comparison
to it, the relative expression levels of UGTs 1A1, 1A6, 1A7, 1A8,
2A1, 2B4, 2B7 and 2B17 were 1.43, 1.69, 23.02, 2.08, 2.79, 0.65,
7.00 and 2.67, respectively. The ‘‘expression normalized’’
glucuronidation rates were calculated by dividing the measured
glucuronidation rates with relative expression level of the each
given recombinant UGT. One of the reasons for carrying out rates
normalization (or correction according to relative expression
levels) was to avoid the very high (but not realistic when compared
to other UGTs) glucuronidation rates by UGTs 1A7 and 2B7, the
enzymes that had the highest relative expression levels in the
batches that were used in this study, 23 and 7, respectively. The
relative expression levels of the other UGT enzymes exhibited
much less variability and their ‘‘normalized’’ glucuronidation rates
were generally similar to the ‘‘measured’’ rates. Due to lack of
appropriate His-tag, the expression level of the commercial
recombinant UGT2B15 could not be determined and, conse-
quently, the results with this UGT are presented as the measured
glucuronidation rates.
Analytical Methods
The HPLC system consisted of an Agilent 1100 series degasser,
binary pump, 100-vial autosampler, thermostated column com-
partment, multiple wavelengths UV detector, and fluorescence
detector (Agilent Technologies, Palo Alto, CA, USA). For all
HPLC separations we have used Poroshell 120 EC-C18 column
(4.66100 mm, 2.7 mm; Agilent Technologies, Palo Alto, CA,
USA), column temperature of 40uC, and eluent flow rate of
1 mL/min. The resulting chromatograms were analyzed with
Agilent ChemStation software (rev. B.01.01) on Windows XP
Professional. The specific details of used analytical methods are
presented in Table 1. The UPLC system consisted of a Waters
Acquity UPLC equipped with column manager, sample manag-
er, binary solvent pump, and photodiode array UV detector
(Waters, Milford, MA, USA). The UV detector was equipped
with high-sensitivity 2.4 mL flow cell. For UPLC separations we
have used Acquity UPLC BEH C18 (2.16100 mm, 1.7 mm,
Waters, Milford, MA) column equipped with a pre-column,
column temperature of 40uC, and flow rate of 0.5 mL/min. The
resulting chromatograms were analyzed with Empower 2
software (Build 2154, Waters, Milford, MA, USA) on Windows
Albumin Effects in Ten Human UGTs
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XP Professional operating system. All specific details of the
analytical conditions are presented in Table 1. The limits of
detection and quantification were estimated based on signal-to-
noise ratios of 3 and 10, respectively.
Analysis of Enzyme Kinetics
The enzyme kinetic parameters were obtained by fitting kinetic
models to the experimental data using GraphPad Prism version
5.04 for Windows (GraphPad Software Inc., San Diego, CA,
USA). The best model was selected based on visual inspection of
the Eadie-Hofstee plots, residuals graphs, parameter S.E. and 95%
confidence intervals estimates (95% CI), the calculated r2 values,
and corrected Akaike’s information criterion. In assays containing
BSA, the total concentrations of substrate were corrected
according to the measured drug binding to BSA, under the
specific conditions of each glucuronidation assay. The statistical
significance of the difference in enzyme kinetics parameters upon
BSA addition was tested with extra sum-of-squares F-test (included
in the GraphPad software, [20]. The initial glucuronidation rates
were fitted to the following equations:
Michaelis-Menten Model
v~
Vmax S½ 
Kmz S½  ð1Þ
Where v is the initial velocity of the enzyme-catalyzed reaction,
[S] is the substrate concentration, Vmax is the limiting reaction
velocity at saturating substrate concentrations, and Km is the
Michaelis-Menten constant (concentration of substrate at 0.5 of
Vmax).
Substrate Inhibition Model
v~
Vmax S½ 
Kmz S½ (1z S½ Ksi )
ð2Þ
Where the Ksi constant describes substrate inhibition in a
mechanism in which a substrate molecule binds to an already
Table 1. Analytical conditions in the separation and quantification of glucuronides.
Analyte Instrument Eluents and gradient
Injection
volume
Detection
parameters
Retention
time
Quantification; LOD and
LOQ1
mL wavelength, nm min Standard curve; mM
4-MU-b-D-glucuronide HPLC A: 0.1% Formic acid; B: Acetonitrile;
0–3 min, 20R50% B; 3–3.1 min,
50R20% B; 3.1–5 min, 20% B
5–40 Fluorescence,
lex 316, lem 382
3.33 Authentic standard; 0.001,
0.003
1-Naphthol-b-D-
glucuronide
HPLC A: 0.1% Formic acid; B: Acetonitrile;
0–3 min, 30R50% B; 3–4 min, 50% B;
4–4.1 min, 50R30% B; 4.1–6 min,
30% B
20 Fluorescence,
lex 282, lem 335
2.30 Authentic standard; 0.001,
0.003
Entacapone-b-D-
glucuronide
UPLC A: 50 mM Phosphate buffer, pH 3.0;
B: Acetonitrile; 0–3 min, 20R30% B;
3–3.2 min, 30R80% B; 3.2–4 min,
80% B; 4–4.1 min, 80R20% B;
4.1–6 min, 20% B
20–40 UV, 309 2.18 Authentic standard; 0.052,
0.172
17b-Estradiol-3-b-D-
glucuronide and 17b-
Estradiol-17-b-D-
glucuronide
HPLC A: 50 mM Phosphate buffer, pH 3.0; B:
Acetonitrile; 0–2 min, 25% B; 2–5 min,
25R50% B, 5–9 min, 50% B, 9–9.1 min,
50R25% B, 9.1–10 min, 25% B
20–50 UV, 225;
Fluorescence,
lex 225, lem 312
4.66 and 5.26 3-glucuronide based on
17b-estradiol’s UV
absorption2; 0.066, 0.221
(UV); 0.019, 0.065 (FLD); 17-
glucuronide authentic
standard; 0.007, 0.024
17a-Estradiol-3-b-D-
glucuronide and 17a-
Estradiol-17-b-D-
glucuronide
HPLC A: 50 mM Phosphate buffer, pH 3.0; B:
Acetonitrile; 0–2 min, 25% B; 2–5 min,
25R50% B, 5–9 min, 50% B, 9–9.1 min,
50R25% B, 9.1–10 min, 25% B
20 Fluorescence
lex 230, lem 308
5.01 and 5.71 Based on 17a-estradiol’s UV
absorption2; 0.078, 0.283
(UV); 0.017, 0.068 (FLD)
6-Hydroxyindole-b-D-
glucuronide
HPLC A: 0.1% Formic acid; B: Acetonitrile;
0–6 min, 10R50% B; 6–6.8 min,
50% B; 6.8–6.9 min, 50–10% B;
6.9–10 min, 10% B
20 UV, 268;
Fluorescence,
lex 268, lem 350
4.02 Based on 6-hydroxyindole’s
UV absorption2; 0.287, 0.955
(UV); 0.001, 0.003 (FLD)
17b-Estradiol HPLC A: 50 mM Phosphate buffer, pH 3.0; B:
Acetonitrile; Isocratic, 2.5 min, 60% B
50 Fluorescence,
lex 216, lem 313
2.10 Authentic standard; 0.004,
0.014
17a-Estradiol HPLC A: 20% Acetonitrile; B: Acetonitrile;
Isocratic. 2.5 min, 55% B
50 Fluorescence,
lex 268, lem 296
1.75 Authentic standard; 0.005,
0.016
6-Hydroxyindole HPLC A: 0.1% Formic acid; B: Acetonitrile;
Isocratic, 3 min, 40% B
40 UV, 268 1.68 Authentic standard; 0.060,
0.201
1LOD, limit of detection; LOQ, limit of quantification; values are calculated assuming maximal injection volume;
2The UV signal for was correlated with fluoresence for enhanced sensitivity.
doi:10.1371/journal.pone.0054767.t001
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formed enzyme-substrate complex, and thus acts as an uncom-
petitive inhibitor of the reaction.
Sigmoidal Model (Hill Equation)
v~
Vmax S½ h
Khmz S½ h
ð3Þ
Where S50 is the substrate concentration at 0.5 of Vmax
(analogous to Km in Michaelis-Menten model), and h is the Hill
coefficient.
Biphasic Model [21]
v~
Vmax 1 S½ zCLint S½ 2
Km1z S½  ð4Þ
Where Vmax1 and Km1 are estimated from the curved portion of
the plot at lower substrate concentrations. The CLint represents
the ratio of Kmax2/Km2 and describes the linear portion of the plot
at higher concentrations of substrate.
For reactions that follow the Michaelis-Menten or substrate
inhibition saturation profile, the intrinsic clearance was calculated
as CLint =Vmax/Km. For reactions exhibiting sigmoidal kinetics,
however, we calculated the maximum clearance, CLmax, an
alternative parameter that expresses the clearance of fully
activated enzyme before the saturation [22]:
CLmax~
Vmax
S50
(h{1)
h(h{1)
1
h
ð5Þ
The relative Km, Vmax, CLint, and CLmax in the presence of BSA
were calculated as X~
B
A
100, where B and A are the
corresponding enzyme kinetic parameters in the presence and
absence of BSA, respectively. The errors for X were estimated
based on the general equation for the propagation of independent
and random errors dX~X
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
dA
A
 2
z
dB
B
 2s
, where X, A, and
B are the average values, and dX, dA, and dB are the corresponding
errors [23]. The errors for CLmax were calculated according to the
general equation for the propagation of uncertainty in a function
of several variables dx~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
Lx
La
da
 2
z
Lx
Lb
db
 2
z
Lx
Lc
dc
 2s
,
where a is Vmax, b is S50, c is h, and da, db, and dc are the
corresponding errors [23].
Results
In this study we have employed six different aglycone substrates
to examine the BSA effects in ten different UGT enzymes. The
substrates were 17a-estradiol (also called 17-epiestradiol), 17b-
estradiol (the physiological estradiol), entacapone, 6-hydroxyin-
dole, 1-naphthol, and 4-MU (Fig. 1). The desire to include the two
estrogens in this study, due to their suitability for studies with
many human UGTs [24] was one of the major reasons to use a
lower BSA concentration than previously used in most studies,
particularly since results from our laboratory demonstrated that
most of the BSA effects are detectable in the presence of 0.1% and
there is no real need to use 2% BSA in such assays [8]. Out of the
ten UGT enzymes, 1A7, 1A8, 1A10, 2A1, 2B15, and 2B17 have
not been tested for BSA effects before, while the remaining four,
UGTs 1A1, 1A6, 2B4, and 2B7, were tested previously, mostly
with other substrates [4–6,10,12] and partly serve as positive
controls in this study.
Binding of Substrates to 0.1% BSA and to Control Insect
Cell Membranes
Added albumin in the UGT assays often binds aglycone
substrates and decreases their actual concentration in solution.
Therefore, in order to reach meaningful conclusions about the
BSA effects on the dependence of glucuronidation rates on
substrate concentration, it is necessary to accurately measure the
unbound fraction of the substrate (fu values) at the given BSA
concentration. For three out of six selected substrates in this study,
1-naphthol, 4-MU and entacapone, we have previously deter-
mined the respective fu values in the presence of either 0.1% or 1%
BSA [8].
In this study, we measured the binding of 17a-estradiol, 17b-
estradiol, and 6-hydroxyindole to 0.1% BSA and to control insect
cell membranes by RED assays [8]. The binding of 17a- and 17b-
estradiol to 0.1% BSA was independent of substrate concentration
and yielded fu values of 0.4960.01 and 0.4860.01 (average 6
S.E.), respectively, indicating that the stereochemistry at carbon C-
17 does not affect the binding of estradiols to albumin. The fu
values in the presence of 0.1% BSA (above) are much higher than
Figure 1. The chemical structures of the substrates that were
used in this study. In 17a- and 17b-estradiol both the 3-OH and the
17-OH can be conjugated, mostly by different UGTs (see Figs. 2 and 3).
In the case of entacapone, the glucuronidation occurs on hydroxy
group in position 3.
doi:10.1371/journal.pone.0054767.g001
Albumin Effects in Ten Human UGTs
PLOS ONE | www.plosone.org 5 January 2013 | Volume 8 | Issue 1 | e54767
the values in the presence of 0.5% and 2% BSA, namely fu = 0.1
and 0.04, respectively [10,25], an outcome that makes full kinetic
analysis of these estradiols glucuronidation much easier. Never-
theless, it should be noted that, for solubility reasons, the fu values
of estradiols binding to 0.1% BSA were measured in the presence
of 1% DMSO, the same concentration that was used in 17a- and
17b-estradiol glucuronidation assays. It is noteworthy that the
presence of 1% DMSO in the reaction mixture does not reduce
the estradiol glucuronidation activity of the human UGTs [15].
Nevertheless, this issue was re-examined here by testing the 1%
DMSO influence on entacapone glucuronidation by UGT1A8, in
both the absence and presence of 0.1% BSA. Entacapone was
selected since its solubility was independent of presence or absence
of DMSO (see below). It was found that addition of 1% DMSO
resulted in only a minor reduction of the UGT activity (#15%),
and did not significantly affected the enzyme kinetic parameters or
the stimulatory effects of 0.1% BSA addition.
The binding of 6-hydroxyindole to 0.1% BSA was generally
low, but partly concentration dependent, yielding high fu values,
0.84–0.97 at 5–750 mM substrate concentration. In order to
estimate the fu at any given concentration of 6-hydroxyindole, we
fitted the experimental data points with empirical equation, and
estimated the fu from the interpolated function (data not shown).
The binding of 17a-estradiol, 17b-estradiol, and 6-hydroxyin-
dole to 0.2 mg/mL of control insect cell membrane (total protein
in the membrane), the highest protein concentration used in this
work, was negligible.
Experiments to Optimize the Assay Conditions of Enzyme
Kinetic Analyses
Prior to enzyme kinetic assays, we performed preliminary tests
to find the optimal experimental conditions for each analysis. The
main focus of these experiments was on optimizing the BSA
concentration, the protein concentration (total protein concentra-
tion in the UGT-enriched insect cells membranes), and possible
need for DMSO addition (if clearly advantageous at high substrate
concentration, it is best be included already with low concentra-
tions of the given substrate). We included 1% DMSO in the assays
with 17a- and 17b-estradiol, as well as in the assays with high
concentrations of 4-MU and 1-naphthol (when [S] $1000 mM).
Addition of 1% DMSO in these cases was necessary due to poor
aqueous solubility of estradiols [26], as well as visually observed
precipitation of substrates and poor reproducibility that we have
observed in preliminary assays with high concentrations of 4-MU
and 1-naphthol. DMSO addition had no significant effect on the
solubility of entacapone and 6-hydoxyindole (results not shown)
and, therefore, it was not included in assays using these two latter
substrates.
In preliminary experiments with UGT1A7, UGT1A10 and
UGT2A1, using 4-MU as a common substrate, enzyme kinetic
assays were performed in the presence of either 0.1% or 1% BSA.
The results of these experiments were in good agreement with the
already published results with UGT1A9 [8], namely only a small
increase of enzyme activity was achieved by replacing 0.1% with
1% BSA. Specifically, the addition of 1% BSA, compared to 0.1%,
resulted in approximately 20–30% of further Km decrease and 10–
15% of increase in Vmax values, depending on the enzyme source.
These results are in good agreement with published data on 4-MU
glucuronidation that were performed in the presence of both 0.1
and 1% BSA, using UGTs 2B7 and 1A9 that were expressed in
HEK293 cells [5,6]. Similar to our results, somewhat higher
degree of the 4-MU Km decrease, by about 20 to 30%, was
observed when 1% of BSA was used instead of 0.1% BSA [5,6].
The use of 1% BSA instead of 0.1% BSA, however, led to a more
profound Km decrease, 48%, in propofol glucuronidation by
UGT1A9 that was expressed in HEK293 cells [6], whereas the use
of 2% BSA instead of 0.1% had very little effect on darexaban
glucuronidation by UGT1A9 that was expressed in Sf9 insect cells
[7]. It is also worth pointing out that, for yet unclear reasons,
previous reports on the BSA effects in UGT1A9 disagree on
whether or not BSA addition increases reactions Vmax, regardless if
0.1, 1, or 2% BSA was used [6–10]. Taken together with the
binding assays outcomes, our results indicate that the potential
benefits of using 1% BSA are offset by much higher nonspecific
binding of substrates, especially in the case of entacapone and
estradiols (fu ,0.1), binding that would have prevented us from
performing enzyme extensive kinetic assays with these substrates.
We then tested the BSA effects on 4-MU glucuronidation by
UGT2A1, using different amounts of total UGT-enriched
membrane protein, 0.02, 0.05, 0.1, 0.2, 0.5, and 1.0 mg/mL.
The results revealed that 0.1% BSA similarly (and strongly)
enhances the UGT2A1 activity in the presence of up to 0.5 mg/
mL of total protein, while its effect in the presence of 1.0 mg/mL
Figure 2. Enzyme kinetics of UGT1A7-catalyzed glucuronida-
tion of entacapone (A) and 4-MU (B) in the absence and
presence of BSA. The glucuronidation rates are presented as the
average value 6 S.E., and are expression level-normalized values (see
Materials and Methods). The concentrations of substrates were
corrected for binding to 0.1% BSA. The determined enzyme kinetic
parameters are presented in Table 2.
doi:10.1371/journal.pone.0054767.g002
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was lower. Taking this into account, in subsequent enzyme kinetic
analyses we have avoided using any recombinant UGT at higher
than 0.2 mg/mL of total sample protein.
BSA Effects on the Enzyme Kinetics of Human UGTs
We used several new substrates to investigate the BSA effects on
six UGT enzymes that have not been studied before, UGTs 1A7,
1A8, 1A10, 2A1, and 2B15, and 2B17, as well as four UGTs, 1A1,
1A6, 2B4, and 2B7, that were already examined [4–7,10,12]. The
enzyme kinetic curves for the newly tested enzymes are presented
in Figs. 2, 3, 4, 5, 6, 7, whereas Fig. 8 presents our assays for
UGT2B7, the most studied UGT enzyme as far as the BSA effects
are concern [4,5,10]. For the reason of clarity and limited space,
the enzyme kinetic curves for the previously tested enzymes,
UGT1A1, UGT1A6 and UGT2B4, are presented in supplemen-
tary material, even if these assay conditions, BSA concentration
and substrates selection, differ between the new assays to the
previous ones (Fig. S1, S2, S3). The calculated enzyme kinetic
parameters for the UGTs of subfamily 1A are presented in Table 2,
whereas the corresponding results for the UGTs of subfamilies 2A
and 2B are given in Table 3.
The principal aim of the current enzyme kinetics assays was to
examine the influence of BSA addition on substrate affinity (Km or
S50) and reaction limiting velocity (Vmax). Due to the large number
of experiments, significant differences in the assays with and
without BSA, as well as the common appearance of substrate
inhibition or sigmoidal kinetics, we could not examine each
individual reaction in full detail. As a result, the determined
enzyme kinetic parameters may be regarded as close estimates,
especially in the case of very high affinity substrates (17a-estradiol
glucuronidation by UGT2B7) or reactions that follow sigmoidal
saturation profile. The detailed mechanistic understanding of
reactions that exhibit sigmoidal kinetics may require the use of
multi-site kinetic models [27–30], a topic that is outside of the
focus of the current study.
In order to ascertain the statistical significance of the found
differences between enzyme kinetic parameters determined in the
absence and presence of BSA, we performed an extra sum-of-
squares F-test for each pair of parameters. The result of this
statistical analysis, as well as the calculated p-values for the
respective Km and Vmax pairs, are presented in Tables 2 and 3. In
addition, for a comparison of BSA affects across different UGTs,
we have presented the relative changes of kinetic parameters in
different UGTs, in the glucuronidation of different substrates, in a
supplementary figure (Fig. S4). For this broad comparison we
calculated the average relative Km, Vmax, and CLint or CLmax in
the presence of BSA, as well as the corresponding propagated S.E.
of the average that includes the errors of enzyme kinetic
parameters from the reactions in both the presence and absence
of BSA (see Materials and Methods for further details). In some
assays, however, especially in the cases of 4-MU and 1-naphthol
glucuronidation, the enzyme kinetics was best described by
sigmoidal model (eq. 3) and, therefore, the S50 value, not the
Km, was taken as a measure for substrate affinity. Nevertheless, for
Figure 3. Enzyme kinetics of UGT1A8-catalyzed glucuronida-
tion of 17b-estradiol (A), entacapone (B), 1-naphthol (C), and 4-
MU (D) in the absence and presence of BSA. The reactions with
17b-estradiol were analyzed for the formation of 17b-estradiol-3-b-D-
glucuronide. The glucuronidation rates are presented as the average
value 6 S.E., and are expression level-normalized values. The
concentrations of substrates were corrected for binding to 0.1% BSA.
The determined enzyme kinetic parameters are presented in Table 2.
See Materials and Methods for all further details.
doi:10.1371/journal.pone.0054767.g003
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simplicity and in order to present the overall picture of the relative
changes in substrate affinity due to the presence of 0.1% BSA, the
relative Km and S50 changes in Fig. S4 were combined.
Enzyme Kinetic Parameters in the Absence of BSA
The results revealed that the enzyme kinetic parameters, for the
tested UGTs, in the absence of BSA (Tables 2 and 3) were mainly
similar to those in the previous reports on 17a- and 17b-estradiol
[24], 4-MU and 1-naphthol [27,31], and entacapone glucuronida-
tion [32]. In most cases, but not all, the addition of 0.1% BSA
influenced the enzyme kinetics of the tested enzymes. The exact
effects, however, were dependent on both the tested enzyme and
the used substrate.
Figure 4. Enzyme kinetics of UGT1A10-catalyzed glucuronida-
tion of 17a-estradiol (A), 17b-estradiol (B), entacapone (C), and
4-MU (D) in the absence and presence of BSA. The reactions with
17a-estradiol and 17b-estradiol were analyzed for the formation of 17a-
estradiol-3-b-D-glucuronide and 17b-estradiol-3-b-D-glucuronide, re-
spectively. The glucuronidation rates are presented as the average
value 6 S.E., and are expression level-normalized values. The
concentrations of substrates were corrected for binding to 0.1% BSA.
The determined enzyme kinetic parameters are presented in Table 2.
See Materials and Methods for all further details.
doi:10.1371/journal.pone.0054767.g004
Figure 5. Enzyme kinetics of UGT2A1-catalyzed glucuronida-
tion of 6-hydroxyindole (A) and 4-MU (B), in the absence and
presence of BSA. The glucuronidation rates are presented as the
average value 6 S.E., and are expression level-normalized values. The
concentrations of substrates were corrected for binding to 0.1% BSA.
The determined enzyme kinetic parameters are presented in Table 3.
See Materials and Methods for all further details.
doi:10.1371/journal.pone.0054767.g005
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BSA Effects on the Km (or S50) Values of UGT-catalyzed
Reactions
Among the newly tested enzymes, the inclusion of 0.1% BSA
led to significant decreases of Km values in UGTs 1A7, 1A8, 1A10,
2A1, and 2B15 (kinetic curves in Figs. 2, 3, 4, 5, 6, parameters in
Tables 2 and 3). The effect was most pronounced in UGT2A1 (up
to 20-fold) followed by UGT1A10 (Table 2). The Km values of
2B17, the last previously untested enzyme, were much less
affected, exhibiting a significant but mild decrease only with one
substrate, 17b-estradiol (Fig. 7, Table 3).
In many cases the BSA effects on the Km values appeared
relatively independent of the used substrate, but deviation from
this rule was observed in UGT2B15, UGT2B17, and especially
UGT1A8. For UGT1A8 the addition of BSA sharply decreased
Km value when assayed for the glucuronidation of the relatively
large substrates, entacapone and 17b-estradiol (Fig. 1), whereas no
Km decrease was found for UGT1A8 when the glucuronidation of
the smaller substrates, 4-MU and 1-naphthol, was examined (Fig. 3
and Table 2).
In the group of previously tested enzymes, the inclusion of 0.1%
BSA led to significant Km value decreases in UGTs 2B4 and 2B7
(Table 3), whereas the Km values of UGTs 1A1 and 1A6 were
relatively unaffected (Table 2). These results are in good
agreement with previous reports on the BSA effects in UGT2B4
[12], UGT2B7 [4,5], as well as UGTs 1A1 and 1A6 [6], all of
which employed 2% BSA.
Figure 6. Enzyme kinetics of UGT2B15-catalyzed glucuronida-
tion of 17a-estradiol (A) and 4-MU (B), in the absence and
presence of BSA. The reaction with 17a-estradiol was analyzed for the
formation of 17a-estradiol-3-b-D-glucuronide. The glucuronidation
rates are presented as the average value 6 S.E. These values are not
expression normalized because we used commercial UGT2B15 without
appropriate His-tag. The concentrations of substrates were corrected
for binding to 0.1% BSA. The determined enzyme kinetic parameters are
presented in Table 3. See Materials and Methods for all further details.
doi:10.1371/journal.pone.0054767.g006
Figure 7. Enzyme kinetics of UGT2B17-catalyzed glucuronida-
tion of 17b-estradiol (A), 1-naphthol (B), and 4-MU (C), in the
absence and presence of BSA. The reaction with 17b-estradiol was
analyzed for the formation of 17b-estradiol-17-b-D-glucuronide. The
glucuronidation rates are presented as the average value6 S.E., and are
expression level-normalized values. The concentrations of substrates
were corrected for binding to 0.1% BSA. The determined enzyme kinetic
parameters are presented in Table 3. See Materials and Methods for all
further details.
doi:10.1371/journal.pone.0054767.g007
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BSA Effects on the Vmax Values
TheBSAeffectson theVmaxvaluesof thedifferentUGTsappeared
unrelated to thecorrespondingeffects on theKmvalues (kinetic curves
inFigs.2,3,4,5,6,7,Tables2and3, summary inFig.S4).Significant,
sometime large,Vmax increaseswereobservedand, interestingly, they
were substrate-dependent in most cases. The highest Vmax increase
was found in UGT1A7 (Fig. 2, Table 1), up to 7-fold. Significant but
strongly substrate-dependentVmax increaseswere found inUGT1A1
and UGT1A10 (Table 2), whereas in UGTs 1A8, 2A1, 2B4, 2B7,
2B15and2B17no largeVmax increaseswere observedwith anyof the
2–3 tested substrates (Table 2 and 3).
BSA Effects on the CLint and CLmax Values
The BSA-induced changes in the CLint values of the different
reactions were mostly large (Fig. S4, note the log10 of the y-axis
scale). The CLint, in addition to simply being the Vmax/Km ratio,
may also be regarded as a fundamental parameter of the
Michaelis-Menten equation, with the physical meaning of a
second-order rate constant for the overall glucuronidation reaction
at low substrate concentrations. Examining the BSA effect on this
constant is interesting since it is affected by changes in both the
Vmax and the Km values. It should be noted, however, that in the
case of substrates that follow sigmoidal kinetics (eq. 3) we
calculated the CLmax, the maximal clearance that results from
autoactivation (eq. 5) [22].
From the perspective of CLint increase, UGT2A1 and UGT1A7
are in a group of enzymes that are highly affected by BSA, even if
they differ largely in the kinetic constants that are most affected by
BSA addition (Km in UGT2A1, but mainly Vmax in UGT1A7).
A plot of the BSA effect on the Km values against the
corresponding effects on the Vmax values (Fig. S5) revealed no
meaningful correlation between the BSA effects on the two kinetic
parameters.
Possible Effects of Assay Conditions on the Observed BSA
Effects
In carrying out the large number of glucuronidation reactions
that were done in this study, it is possible that some samples were
handled somewhat differently from others. Hence, the large and
substrate-dependent BSA effects in some cases, prompted us to
examine whether or not there is a correlation between the BSA
effects and the assay conditions. The results of these experiments
are presented in the supplementary materials (Fig. S6) and they
show no correlation between the magnitude of the BSA effects and
assay conditions, such as the incubation time or total concentra-
tion of UGT protein during the reaction.
Discussion
BSA addition enhances the in vitro activities of several UGTs
and improves in vitro–in vivo extrapolation [4–10,12,33,34]. Not
enough, however, is known and understood about the extent and
mechanism of the BSA effects. The principle goal of this work was
to investigate these effects in six previously untested UGT
enzymes, UGTs 1A7, 1A8, 1A10, 2A1, 2B15, and 2B17, as well
as to reexamine part of the previously studied BSA effects on
UGTs 1A1, 1A6, 2B4, and 2B7 with a more diverse set of
substrates in order to find out whether or not the BSA effects are
dependent on the used substrate.
Six different UGT substrates, 17a-estradiol, 17b-estradiol,
entacapone, 6-hydroxyindole, 1-naphthol, and 4-MU, were used
for enzyme kinetic assays, in both the absence and presence of
BSA. The results were calculated following the determination of
their fu in the presence of 0.1% BSA and the used enzymes source.
The selected UGT substrates have different physicochemical
properties and a wide distribution of enzyme kinetic parameters,
providing together a good representation of the chemical space
Figure 8. Enzyme kinetics of UGT2B7-catalyzed glucuronida-
tion of 17a-estradiol (A), 17b-estradiol (B), and 4-MU (C), in the
absence and presence of BSA. The reactions with 17a-estradiol and
17b-estradiol were analyzed for the formation of 17a-estradiol-17-b-D-
glucuronide and 17b-estradiol-17-b-D-glucuronide, respectively. The
glucuronidation rates are presented as the average value6 S.E., and are
expression level-normalized values. The concentrations of substrates
were corrected for binding to 0.1% BSA. The determined enzyme kinetic
parameters are presented in Table 3. See Materials and Methods for all
further details.
doi:10.1371/journal.pone.0054767.g008
Albumin Effects in Ten Human UGTs
PLOS ONE | www.plosone.org 10 January 2013 | Volume 8 | Issue 1 | e54767
that is typically encountered by UGT enzymes. Most of the
selected substrates allow for sensitive detection in HPLC analyses
(see Table 1 for the limits of detection and quantification),
enabling assays with relatively low concentrations of the UGT-
enriched membrane, up to 0.2 mg/mL of total protein. Under
these conditions, the inclusion of 0.1% BSA was sufficient to
achieve good stimulatory effects in most cases [7–9].
Although assays with 1% BSA, in comparison with assays
including 0.1% BSA, resulted in somewhat better enhancement of
enzyme activity (see Results section), the use of 1% BSA has the
disadvantage of high nonspecific binding of substrates. The use of
Table 2. Enzyme kinetic parameters of UGTs 1A1, 1A6, 1A7, 1A8, and 1A10-catalyzed glucuronidation in the absence and presence
of BSA.
No BSA 0.1% BSA
UGT enzyme/
substrate
Km or S50± S.E.
(95% CI)
Vmax ± S.E.
(95% CI) Model, r2
Km or S50± S.E.
(95% CI)
Vmax ± S.E.
(95% CI) Model, r2
mM nmolNmin–1Nmg–1 mM (S.E.) mM nmolNmin–1Nmg–1 mM (S.E.)
UGT1A1
17a-Estradiol (3-
glucuronide)
4.5760.48
(3.59–5.56)
0.01960.001
(0.018–0.020)
MM, 0.97 4.7960.28
(4.21–5.37)
0.02060.0003
(0.019–0.020)
MM, 0.99
17b-Estradiol (3-
glucuronide)
7.8461.62
(4.48–11.21)
0.1960.01
(0.17–0.21)
MM, 0.89 9.0661.14
(6.70–11.42)
0.2460.01***
(0.23–0.26)
MM, 0.96
1-Naphthol 101611
(78–123)
0.1160.01
(0.10–0.13)
HE, 0.96;
h= 1.88 (0.33)
81.665.1
(71.0–92.1)
0.1760.01**
(0.16–0.18)
HE, 0.98;
h=2.33 (0.31)
4-MU 72.666.9
(58.2–87.0)
0.1160.004
(0.11–0.12)
MM, 0.98 64.268.4{
(46.7–81.7)
0.2560.02{
(0.21–0.29)
SI, 0.99;
Ki = 537 (115)
UGT1A6
6-Hydroxyindole 390678
(227–553)
7.060.8
(5.3–8.7)
SI, 0.98;
Ki = 2800 (576)
300640
(217–382)
8.060.6
(6.8–9.1)
SI, 0.98;
Ki = 2989 (604)
1-Naphthol 8.0760.48
(7.08–9.06)
6.760.1
(6.47–6.94)
MM, 0.99 5.2560.23***
(4.78–5.72)
5.960.1***
(5.8–6.0)
MM, 0.99
4-MU 76.4615.1
(45.3–107.5)
5.260.3
(4.5–6.0)
MM, 0.94 57.562.0
(53.4–61.5)
9.660.1***
(9.4–9.9)
MM, 0.99
UGT1A7
Entacapone 33.264.0
(24.9–41.6)
0.1560.01
(0.14–0.16)
MM, 0.93 17.961.9
(14.0–21.7)
0.9860.03***
(0.93–1.03)
MM, 0.96
4-MU 17.663.1
(11.0–24.2)
0.2560.01
(0.22–0.28)
SI, 0.86;
Ki = 1398
(339)
11.561.4
(8.4–14.5)
0.8660.04***
(0.78–0.94)
SI, 0.95;
Ki = 289 (34)
UGT1A8
17b-Estradiol (3-
glucuronide)
8.1660.55
(7.03–9.30)
0.02060.0003
(0.019–0.021)
MM, 0.99 4.7060.62**
(3.42–5.99)
0.022* 60.001
(0.021–0.023)
MM, 0.95
Entacapone 73.163.7
(65.4–80.7)
1.260.02
(1.2–1.3)
MM, 0.99 26.961.7***
(23.8–30.1)
1.760.02***
(1.6–1.8)
MM, 0.99
1-Naphthol 91.666.6
(78.0–105.3)
2.560.1
(2.3–2.7)
SI, 0.99;
Ki = 435 (40)
105616
(73–137)
3.160.3**
(2.4–3.7)
SI, 0.99;
Ki = 300 (55)
4-MU 13469
(115–154)
1.260.03
(1.2–1.3)
HE, 0.98;
h= 1.49 (0.14)
154611
(132–176)
1.860.1***
(1.7–2.0)
HE, 0.99;
h=1.52 (0.14)
UGT1A10
17a-Estradiol (3-
glucuronide)
25.766.3
(12.8–39.1)
0.07060.006
(0.058–0.082)
MM, 0.92 12.361.8*
(8.5–16.1)
0.1360.01**
(0.12–0.14)
MM, 0.95
17b-Estradiol (3-
glucuronide)
4.5860.61
(3.30–5.85)
2.560.1
(2.3–2.7)
MM, 0.93 1.5660.11***
(1.33–1.80)
4.460.1***
(4.27–4.60)
MM, 0.98
Entacapone 56.762.3
(51.9–61.5)
0.9160.01
(0.89–0.94)
MM, 0.99 11.260.3***
(10.6–11.9)
2.760.02***
(2.7–2.8)
MM, 0.99
4-MU 80.766.6
(67.0–94.3)
8.060.3
(7.3–8.7)
SI, 0.99;
Ki = 2289 (425)
19.261.3***
(16.6–21.8)
7.860.2
(7.48–8.22)
SI, 0.99;
Ki = 855 (71)
The glucuronidation rates are presented as expression level-normalized values 6 S.E. The 95% CI are presented in the parenthesis. The p-values were calculated using
the extra sum-of-squares F-test (see Materials and Methods for all details).
MM, Michaelis-Menten; SI, substrate inhibition; HE, Hill equation;
*P,0.05;
**P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0054767.t002
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0.1% BSA, rather than 1 or 2%, significantly lowered the
nonspecific binding and enabled us to carry out more accurately
assays with physiologically relevant compounds, such as estradiol
and the therapeutic drug entacapone. Although clearly a
compromise, this strategy offers an advantage over assays that
combine high concentrations of albumin (1 or 2%) with
hydrophobic UGT substrates or inhibitors. For example, Walsky
et al. (2012) performed enzyme kinetic assays with 17b-estradiol in
the presence of 2% BSA, conditions under which the fu of 17b-
estradiol is very low, barely 0.04. A similar problem was
encountered in a substrate depletion study with a number of
hydrophobic drugs [34], as well as in inhibition assays with
spironolactone [35] and niflumic acid [36]. In the latter case BSA
was omitted from the assays due to excessive nonspecific binding
of the inhibitors. Taken together, we think that the use of 0.1%
BSA is a reasonable compromise between good activation of UGT
enzymes and relatively low nonspecific binding of substrates to
BSA. An alternative solution for high nonspecific binding of
substrates and inhibitors may be the previously suggested
replacement of BSA with intestinal fatty acid binding protein
[25]. The advantage of this expensive alternative over the use of
0.1% BSA, however, has still to be tested with more enzymes and
substrates.
The addition of 0.1% BSA significantly enhanced the activities
of most human UGTs. Nevertheless, it is worth noting that there
was a significant difference in the routes that lead to this
enhancement, as well as in its degree. In some of the enzymes,
namely the stimulation was through a Km decrease (UGTs 1A7,
1A8, 1A10, 2A1, and 2B15 of the UGTs that were not previously
Table 3. Enzyme kinetic parameters of UGTs 2A1, 2B4, 2B7, 2B15, and 2B17-catalyzed glucuronidation in the absence and
presence of BSA.
No BSA 0.1% BSA
UGT enzyme/substrate
Km or S50±
S.E. (95% CI)
Vmax ± S.E. (95%
CI) Model, r2
Km or S50± S.E.
(95% CI)
Vmax ± S.E. (95%
CI) Model, r2
mM nmolNmin–1Nmg–1 mM (S.E.) mM nmolNmin–1Nmg–1 mM (S.E.)
UGT2A1
6-Hydroxyindole 14746121
(1223–1724)
0.7960.04
(0.72–0.87)
MM, 0.99 56.662.3***
(51.8–61.4)
1.260.01***
(1.17–1.22)
MM, 0.99
4-MU 48.164.8
(38.2–57.9)
2.160.1
(1.9–2.1)
MM, 0.97 2.7360.20{
(2.41–3.05)
2.160.02{
(2.1–2.2)
SI, 0.97;
Ki = 2045 (255)
UGT2B4
17a-Estradiol (17-glucuronide) 4.5160.68
(3.09–5.93)
0.05360.002
(0.048–0.058)
MM, 0.95 1.6060.23***
(1.12–2.08)
0.04760.002
(0.044–0.050)
MM, 0.91
1-Naphthol 210612
(186–235)
0.02560.001
(0.023–0.027)
HE, 0.96;
h= 2.62 (0.36)
99.867.5***
(84.3–115.4)
0.008060.0032***
(0.0074–0.0087)
HE, 0.89;
h= 4.13 (1.00)
4-MU 298643
(210–387)
0.04360.002
(0.039–0.047)
MM, 0.95 192615*
(161–222)
0.03560.001***
(0.033–0.037)
MM, 0.98
UGT2B7
17a-Estradiol (17-glucuronide) 0.12860.015
(0.098–0.158)
0.01460.0003
(0.014–0.015)
MM, 0.96 0.037960.0065***
(0.0242–0.0515)
0.01660.0003***
(0.016–0.017)
MM, 0.97
17b-Estradiol (17-glucuronide) 2.5660.29
(1.96–3.16)
0.006760.0003
(0.0062–0.0072)
MM, 0.96 0.83260.096***
(0.633–1.031)
0.006360.0002
(0.0059–0.0067)
MM, 0.94
4-MU 301665
(165–436)
0.2860.03
(0.22–0.34)
HE, 0.93; h= 1.75
(0.46)
212617
(177–247)
0.3960.01*
(0.36–0.42)
HE, 0.99;
h= 2.01 (0.24)
UGT2B15
17a-Estradiol (3-glucuronide) 10.261.0
(8.0–12.3)
0.06960.003
(0.062–0.076)
SI, 0.99;
Ki = 360 (92)
5.5860.56***
(4.24–6.74)
0.08560.003**
(0.077–0.092)
SI, 0.98;
Ki = 348 (80)
4-MU 29.660.9
(27.6–31.5)
0.8360.01
(0.82–0.85)
MM, 0.99 7.0660.30***
(6.54–7.54)
0.5360.01***
(0.53–0.54)
MM, 0.99
UGT2B17
17b-Estradiol (17-glucuronide) 6.0160.26
(5.47–6.54)
0.01360.0002
(0.0125–0.0132)
MM, 0.99 4.0160.24***
(3.51–4.51)
0.01360.0002
(0.0126–0.0134)
MM, 0.98
1-Naphthol 540626
(485–595)
0.2860.01
(0.26–0.31)
MM, 0.99 484627
(427–541)
0.3460.02**
(0.30–0.37)
MM, 0.99
4-MU 377642
(291–463)
0.05060.002
(0.049–0.058)
MM, 0.99 383629
(322–444)
0.06860.002 ***
(0.064–0.072)
MM, 0.99
The glucuronidation rates are presented as expression level-normalized values 6 S.E., except for the commercial UGT2B15. The 95% CI are presented in the parenthesis.
The p-values were calculated using the extra sum-of-squares F-test (see Materials and Methods for all details).
MM, Michaelis-Menten; SI, substrate inhibition; HE, Hill equation;
*P,0.05;
**P,0.01;
***P,0.001.
doi:10.1371/journal.pone.0054767.t003
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tested) that was accompanied by Vmax increases in two of them,
UGT1A7 and UGT1A10 (Figs. 2, 3, 4, 5, 6, 7, Tables 2 and 3).
It is also important to note that there is a clear variability in the
BSA effects on the human UGTs. For example, while UGTs 2B7
and 2B17 interact with similar type of substrates, estradiols, the
BSA effects on UGT2B7 are much larger than on UGT2B17. In
addition, with 4-MU as the substrate, we have found a significant
Vmax increase in both UGT1A1 and 1A6, whereas in the case of 1-
naphthol glucuronidation the inclusion of BSA in the reaction
mixture increased the Vmax value of UGT1A1, but not UGT1A6
(Figs. S1 and S2, Table 2).
Although our understanding of the Km and Vmax changes is
important for mechanistic studies of BSA effects, the overall
magnitude of activity enhancement, especially at low concentra-
tions of substrate, may be more relevant for studies focused on
in vitro–in vivo extrapolation. Such an overall activity enhance-
ment in the presence of BSA may be better expressed through
relative changes in CLint or, in the case of sigmoidal kinetics,
CLmax (Fig. S4, note the log10 scale of the y-axis). These changes
can simply be interpreted as the combined effects of Km and Vmax
modulation, or, from a slightly different point of view, as the
overall enhancement of enzyme activity at low concentrations of
substrate. The results show that inclusion of 0.1% BSA leads to
large CLint increases in UGTs 1A7, 1A10, and 2A1. The CLint
increase, up to 400-fold, is especially striking in the case of
UGT2A1, an enzyme with broad substrate selectivity, but limited
tissue expression pattern [37].
The BSA effects on the Km values of some, but not all, UGTs
raises questions about the nature of the BSA effects. If the
apparently higher affinity for the substrates in the presence of the
BSA is due to BSA-mediated removal of lipid inhibitors, such as
arachidonic or linoleic acid [5], then the lack of such effects in
UGTs 1A1, 1A6, and 2B17 would mean that these enzymes are
not inhibited by such inhibitors, at least not in the way that
compromises the binding of aglycone substrate. It is also worth
noting that the inclusion of BSA decreases the Km values of the
affected enzymes, even if the substrate affinity is already very high,
as in the case of 17a-estradiol and UGT2B7 (Fig. 8, Table 3). We
recently observed similar phenomena with 1-naphthol and
UGT1A9 [9]. Although surprising as first glance, these results
are generally consistent with the theory of competitive inhibition,
in particular with the fact that the KmI/Km ratio, the ratio of
apparent substrate affinities in the presence (KmI) and absence (Km)
of the inhibitor, is solely dependent on the [I]/Ki ratio, rather than
on the absolute magnitude of the substrate affinity. In line with
this, the tentative UGT inhibitors that are removed by BSA, such
as fatty acids, may exhibit very high affinity toward the enzymes
[5,38,39].
The results with UGT1A8 are of particular interest since in this
enzyme BSA addition led to Km decrease when the larger
substrates, 17b-estradiol and entacapone, were used, but no
changes when 1-naphthol and 4-MU, much smaller molecules
(Fig. 1), were used as the glucuronidation substrates (Fig. 3,
Table 2). This might indicate that the two substrate groups have
unique binding modes, each differently affected by BSA addition.
Additional studies will be needed to fully resolve this phenomenon
and find out if it could be documented in other human UGTs.
In contrast to the BSA effects on the Km values that, with the
exception of UGT1A8, were not highly dependent on the used
substrate, the BSA effects on Vmax values were significantly
influenced by the used substrate (Figs. 2, 3, 4, 5, 6, 7, 8, Tables 2
and 3). A Vmax increase with all tested substrates was only found in
the present study with UGT1A7 and in other studies with
UGT1A9 [8,9] (Fig. 2, Table 1). The considerable BSA-induced
Vmax increases in UGTs 1A1, 1A6, and 1A10 were clearly
substrate dependent (Table 2). These results may indicate that
BSA-induced Vmax increases are mainly limited to the UGT1A
subfamily.
The Vmax value increase in the presence of BSA may be
explained by albumin-mediated removal of noncompetitive of
mixed-type inhibitors with respect to the aglycone substrate [9].
Taking into account the compulsory-order of substrate binding in
UGT-catalyzed reaction [9,31], such inhibitors would also bind to
the ternary enzymeNUDPGANaglycone complex. As structurally
different aglycone substrates may lead to slightly different ternary
complexes, these tentative UGT inhibitors may have different
affinities for them, explaining the differential effects of BSA
inclusion on Vmax values. Moreover, no correlation between
relative Km and Vmax changes was found in this study (Fig. S5),
suggesting that the possible removal of different inhibitors is
responsible for these two independent effects. Considering the
chemical structure of these putative ‘‘Vmax-affecting’’ inhibitors, no
data is currently available, but it could well be one or more of the
fatty acids that bind to BSA.
Our previous study on zidovudine and entacapone glucuroni-
dation in the presence of BSA clearly demonstrated that there are
no major differences in the BSA effects between UGTs in HLM
and recombinant enzymes that were expressed in Sf9 insect cells
[8]. Hence, the presence in Sf9 cells of less linoleic and arachidonic
acid, but more oleic and palmitoleic acid than HLM [5,40] does
not change the BSA effects significantly. Therefore, the current
findings on the BSA effects in the recombinant UGTs (expressed
in Sf9 insect cells) are expected to represent, both qualitatively and
quantitatively, the corresponding BSA effects in HLM. However,
depending on the total amount of an enzyme source in the assay,
the optimal concentration of added BSA may require further
adjustments, especially if more than 0.2 mg/mL total membrane
protein is used, the highest concentration of enzyme source that
we have used in this work.
The mostly comparable BSA effects that were so far found for
UGTs in HLM and recombinant systems, either HEK293 or Sf9
cells, may be different from the corresponding BSA effects in
cytochrome P450 (CYP) assays, however. The latter is suggested
based on reports that the BSA effects in recombinant CYPs 1A2,
2C8, and 2C9 were less pronounced compared to assays with
HLM [41–43]. Nevertheless, these recombinant CYPs could not
be compared to the recombinant UGTs since they were expressed
in bacterial cells, whereas the recombinant UGTs are expressed in
eukaryotic cells. Unfortunately, there is currently no good way to
express recombinant human UGTs in E. coli cells, the system used
for recombinant CYP enzymes expression, and it is impossible to
test in what way the lower abundance of inhibitory fatty acids in
these bacterial cells [43] affects the UGTs and their activity
stimulation by BSA.
In conclusion, we have described the BSA effects in six
previously unexamined human UGTs 1A7, 1A8, 1A10, 2A1,
2B15 and 2B17, and expanded previous findings on the BSA
effects in UGTs 1A1, 1A6, 2B4, and 2B7. The combined results
highlight the complexity and variability of this effect, far different
from the original results with UGT2B7 where the BSA effect is
restricted to the reaction Km value [5]. BSA addition often
increases the reaction’s Vmax, an effect that appears to be
dependent on both the aglycone substrate and the individual
UGT. In addition, there are cases where BSA addition does not
lead to significant activity stimulation or changes in its kinetic
parameters. Taking all the results into account, this work expands
the current knowledge on the different BSA effects, the function
and, perhaps, also the structure of the human UGTs, providing
Albumin Effects in Ten Human UGTs
PLOS ONE | www.plosone.org 13 January 2013 | Volume 8 | Issue 1 | e54767
important results and analysis for future studies on in vitro UGT
assays, as well as further studies on the exact nature and
mechanism of the inhibitors that are removed by BSA.
Supporting Information
Figure S1 Enzyme kinetics of UGT1A1-catalyzed glu-
curonidation of 17a-estradiol (A), 17b-estradiol (B), 1-
naphthol (C), and 4-MU (D), in the absence and presence
of BSA. The reactions with 17a-estradiol and 17b-estradiol were
analyzed for the formation of 17a-estradiol-3-b-D-glucuronide
and 17b-estradiol-3-b-D-glucuronide, respectively. The glucuro-
nidation rates are presented as the average value 6 S.E., and are
expression level-normalized values. The concentrations of sub-
strates were corrected for binding to 0.1% BSA. The determined
enzyme kinetic parameters are presented in Table 2. See Materials
and Methods for all further details.
(TIF)
Figure S2 Enzyme kinetics of UGT1A6-catalyzed glu-
curonidation of 6-hydroxyindole (A), 1-naphthol (B), and
4-MU (C), in the absence and presence of BSA. The
glucuronidation rates are presented as the average value 6 S.E.,
and are expression level-normalized values. The concentrations of
substrates were corrected for binding to 0.1% BSA. The
determined enzyme kinetic parameters are presented in Table 2.
See Materials and Methods for all further details.
(TIF)
Figure S3 Enzyme kinetics of UGT2B4-catalyzed glu-
curonidation of 17a-estradiol (A), 1-naphthol (B), and 4-
MU (C), in the absence and presence of BSA. The reaction
with 17a-estradiol was analyzed for the formation of 17a-estradiol-
17-b-D-glucuronide. The glucuronidation rates are presented as
the average value 6 S.E., and are expression level-normalized
values. The concentrations of substrates were corrected for
binding to 0.1% BSA. The determined enzyme kinetic parameters
are presented in Table 3. See Materials and Methods for all further
details.
(TIF)
Figure S4 The combined effects of BSA of the Km (A),
Vmax (B), and CLint or CLmax (C) of the ten tested human
UGTs. The average values of the enzyme kinetic parameters,
determined in the absence of BSA, where arbitrary assigned to
100%, and the average corresponding values of Km, Vmax, and
CLint or CLmax in the presence of BSA were compared to the
values in the absence of BSA and plotted for all the ten tested
UGT enzymes. The presented errors are propagated S.E. values
that take into account the errors in the parameters determined in
both the absence and presence of BSA (See Materials and Methods
for further details). Due to large increases of CLint or CLmax in the
presence of BSA, the values of y-axis in panel C are presented on a
log10 scale.
(TIF)
Figure S5 The correlation between relative Km and Vmax
values in the presence of 0.1% BSA. The average values of
enzyme kinetic parameters, determined in the absence of BSA,
where arbitrary assigned to 100%, and the average relative values
of Km and Vmax in the presence of 0.1% BSA were plotted against
each other.
(TIF)
Figure S6 The correlation between relative enzyme
kinetic parameters in the presence of 0.1% BSA (Km,
Vmax, and CLint or CLmax) and experimental conditions
of enzyme kinetic assays, namely incubation time
(panels A–C) and total protein concentration (panels
D–E). The average values of enzyme kinetic parameters,
determined in the absence of BSA, were arbitrary assigned to
100%, and the average relative values of Km, Vmax, and CLint or
CLmax in the presence of 0.1% BSA were plotted against
experimental conditions of the corresponding enzyme kinetic
assay. For this analysis, we combined in a single graph panel the
average relative values of enzyme kinetic parameters (in the
presence of BSA) from all ten UGT enzymes and six substrates.
Due to large increases of CLint or CLmax in the presence of 0.1%
BSA, the values of y-axis are presented on log10 scale. The
incubation time varied from 10 to 60 min (panels A–C), and UGT
protein concentration, referring to total protein concentration in
the membrane, varied from 0.02 to 0.2 mg/mL. See Materials and
Methods for all further details.
(TIF)
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